Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS. Reblozyl (luspatercept) has become the new standard ...
Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...
HOUSTON -- Treatment with hypomethylating agents led to objective responses in a majority of patients with low- and intermediate-risk myelodysplastic syndromes (MDS), according to a study reported ...
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved engraftment ...
All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk myelodysplastic syndromes (MDS) ...
Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...
Low-dose Revlimid delayed transfusion dependency and improved treatment response rates in non-transfusion dependent MDS patients. Revlimid reduced the risk of transfusion dependency by 69.8% compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results